A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate‐to‐severe atopic eczema [PDF]
, 2019 Stephan Weidinger, Christian Apfelbacher
openalex +1 more source
Alopecia areata in 2 patients treated with dupilumab: New onset and worsening
, 2019 Janice Chung +2 more
openalex +1 more source
The utility of dupilumab for use in the pediatric population [PDF]
, 2019 Aakaash Varma +2 more
openalex +1 more source
Molecular mechanisms in atopic eczema:insight gained from genetic studies [PDF]
, 2017 Adoue +64 more
core +2 more sources
International Journal of Dermatology, EarlyView.ABSTRACT Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell‐based therapies.
Marcela da Costa Pereira Cestari +2 more
wiley +1 more source
Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study [PDF]
, 2018 Ian Pavord +13 more
openalex
Efficacy of dupilumab in prurigo nodularis in elderly patient
, 2019 Maria Teresa Giura +4 more
openalex +1 more source
Two atopic dermatitis patients in whom dupilumab improved aberrant epidermal protease activities [PDF]
, 2019 Hayato Nomura +3 more
openalex +1 more source
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a case series [PDF]
, 2020 Emma Johansson +4 more
openalex +1 more source
178 Effect of Dupilumab on Global Individual Signs Score Outcomes in Adults With Moderate-to-Severe Atopic Dermatitis: Combined Results From Four Phase 3 Trials [PDF]
, 2019 Petra Staubach +8 more
openalex +1 more source